AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT04209855
Drug: Pegylated liposomal doxorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pegylated liposomal doxorubicin will be administered per dose and schedule specified in the arm.
Trial: NCT01909557
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03453840
Drug: Artemether-lumefantrine
RxNorm normalized name: artemether-lumefantrine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Children will receive the dispersible formulation of AL which contains 20 mg artemether, 120 mg of lumefantrine (Coartem® Dispersible). Weight-based dosing will be as below: \<15kg, 1tablet; 15-25kg, 2 tablets; 25-35kg, 3 tablets; \>=35kg, 4 tablets.
Trial: NCT00850590
Drug: NRL001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Four single doses of NRL001 or placebo. NRL001 is administered at lower (5, 7.5 and 10 mg) or higher (10, 12.5 and 15 mg) doses in a slow release rectal suppository weighing either 1 g or 2 g.
Trial: NCT01451762
Drug: .9 normal saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: .9 normal saline administered before surgery.
Trial: NCT03576599
Drug: Zoledronic Acid Injectable Product
RxNorm normalized name: zoledronic acid Injectable Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One Group are randomiced to Zoledronic Acid Injectable Product and one Group to Placebo
Trial: NCT03576599
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT01491009
Drug: Remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV infusion
Trial: NCT01471847
Drug: BEZ235 + Trastuzumab Phase l/Phase ll)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phase l: Patients will receive increasing doses of oral BEZ235 (BID) together with standard weekly trastuzumab at a fixed dose. BEZ235 doses will be escalated in cohorts of 3 to 6 patients guided by an adaptive Bayesian logistic regression model with overdose control until MTD/RP2D has been established.~Phase ll: If randomized to the trastuzumab + BEZ235 arm, patients will receive standard weekly trastuzumab in combination with oral BEZ235 (BID) at the MTD or RP2D and will continue on study treatment until PD, unacceptable toxicity or until other pre-defined discontinuation criteria are met. They will have regular safety assessments and will be evaluated for response to treatment according to RECIST every 2 cycles for the first 36 weeks then every 12 weeks until disease progression (or start of new anti-neoplastic therapy).
Trial: NCT01471847
Drug: Lapatinib + Capecitabine (Phase II)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: If randomized to the lapatinib + capecitabine treatment arm, patients will receive standard lapatinib plus capecitabine until PD, unacceptable toxicity or until other pre-defined discontinuation criteria are met.~Patients will have regular safety assessments and will be evaluated for response to treatment according to RECIST every 2 cycles for the first 36 weeks then every 12 weeks until disease progression (or start of new anti-neoplastic therapy). After progression, survival f-up will continue.~All patients participating in the Phase II part of the study will be required to have available archival or fresh tumor tissue for biomarker analysis prior to treatment start
Trial: NCT00245609
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00907998
Drug: APL180
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00907998
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01701024
Drug: ACYC
RxNorm normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ACYC active, topically applied to the face for 12 weeks
Trial: NCT02019056
Drug: Placebo /bid P.O
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04722120
Drug: Low contrast dose CT
RxNorm normalized name: Contrased
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Underwent liver CT 20% lower dose contrast media.
Trial: NCT04722120
Drug: Conventional CT (contrast agent)
RxNorm normalized name: Contrased
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Underwent liver CT without change of contrast media doses.
Trial: NCT00863746
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo - 2 tablets twice daily (BID)
Trial: NCT01924858
Drug: GSK2647544 oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK2647544 100 mg will be supplied as a size 0 swedish orange hard gelatin capsules filled with white/slightly colored granule. Subjects will receive a single oral dose of GSK2647544 100 mg (2 X 50mg capsules) with 150 mL of tepid water approximately 2 hours prior to the IV infusion of \[18F\]-GSK2647544 and a PET scan.
Trial: NCT01924858
Drug: [18F]GSK2647544 IV bolus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: \[18F\]GSK2647544 will be supplied as a clear, colourless solution free from visible particle. A maximum dose up to 2 mg with a maximum dose volume of 25 mL will be administered as IV bolus over 60 seconds.
Trial: NCT03043547
Drug: nal-IRI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nal-IRI \[Irinotecan liposome\] (80 mg/m2 as a 1.5 hour infusion)
Trial: NCT03043547
Drug: leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: leucovorin (400 mg/m2 as 0.5 hour infusion)
Trial: NCT02015754
Drug: DEBIRI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irinotecan hydrochloride is a semisynthetic derivative of camptothecin, an alkaloid extracted from the tree Camptotheca acuminata. Irinotecan hydrochloride trihydrate is a pale yellow to yellow crystalline powder, it is mixed in DC Beads and injected in the tumor.
Trial: NCT01434108
Drug: Ornithine-phenylacetate
RxNorm normalized name: phenylacetate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phase A: Open-label scalating dose of OP. Treatment will be initiated at 1/3 of the final dose and will be scalated every 12 hours up to the full dose, except if there are problems of tolerance. Duration of the infusion 5 days.~Phase B: Comparative study of experimental drug vs placebo for 5 days OP (OCR-002) at a dose of 10 g diluted in 150 ml of water for injection administered as a continuous i.v. infusion for 24 hours (8.3 ml/h)during 5 days.
Trial: NCT02933775
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 500 mg/m\^2/day×2 days
Trial: NCT01546805
Drug: Zinc Supplement
RxNorm normalized name: Zinc supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The interventional group will be requested to take zinc supplements (50mg), once daily starting 5 days prior to Botox injections and to be continued for 5 days after injection.
Trial: NCT00650000
Drug: Provigil® Tablets 200 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200mg, single dose fasting
Trial: NCT04084483
Drug: K-161
RxNorm normalized name: K
FDA approved: no
EMA approved: no
PMDA approved: no
Description: K-161 alternate dosage
Trial: NCT01802697
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01362998
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: An infusion of epidural fentanyl started during the Cesarean section. It will be given on a patient controlled analgesia basis, with a basal rate of 60 micrograms, a demand dose of 16 micrograms, and a lockout of 15 mins.
Trial: NCT00097747
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04227886
Drug: Capecitabine-Irinotecan Combination
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The concurrent chemotherapy consists of capecitabine 625 mg/m2 twice daily 5 days per week and combined with weekly irinotecan. The irinotecan dose was used based on UGT1A1 genotype of 80mg/m2 for UGT1A1\*1\*1 or 65mg/m2 for UGT1A1\*1\*28 weekly, followed by a cycle of XELIRI.
Trial: NCT01697579
Drug: 5-hydroxytryptamine 3 antagonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered IV according to local labeling and/or local standard of care
Trial: NCT00761852
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 tab po QD for 2 weeks
Trial: NCT00718549
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide will be administred at a dose of 250 mg/m\^2/day as IV infusion over 15-30 minutes on Days 2-4 of each 28-day cycle during induction phase.
Trial: NCT02493504
Drug: Heparin
RxNorm normalized name: Heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 100units/kg of heparin were administered for the case group after dissection prior to anastomosis.
Trial: NCT03747978
Drug: Perindopril-indapamide
RxNorm normalized name: indapamide / perindopril
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perindopril 5mg and Indapamide 1.25mg
Trial: NCT03130179
Drug: Nicorette Strongmint lozenge 4 mg
RxNorm normalized name: Nicorette Lozenge Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single dose of one Nicorette lozenge 4mg lozenge administrated orally to slowly dissolve in the mouth.
Trial: NCT01253408
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will match study drug; taken orally with water twice per day for two days.
Trial: NCT03851991
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: controle
Trial: NCT00731055
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 dose of placebo
Trial: NCT03247556
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo was administered once daily
Trial: NCT03247556
Drug: 400mg SPN-812
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400mg SPN-812 was administered once daily and compared to Placebo
Trial: NCT03247556
Drug: 600mg SPN-812
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600mg SPN-812 was administered once daily and compared to Placebo
Trial: NCT00388180
Drug: GW501516
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00388180
Drug: GW590735
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03931876
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single ascending dose administration
Trial: NCT01179048
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maximum dose of 1.8 mg placebo, injected subcutaneously (under the skin) once daily. Administered in addition to the subject's standard treatment
Trial: NCT01900730
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient takes placebo capsule 3 times a day by mouth for 10 weeks.
Trial: NCT02107170
Drug: Remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01471808
Drug: CSII
RxNorm normalized name: Continuous Subcutaneous Insulin Infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: continuous subcutaneous insulin infusion for 2\~4 weeks
Trial: NCT01617668
Drug: LCL161
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LCL161 was available as 300 mg, tablets, which was supplied in child-resistant bottles.
Trial: NCT03401112
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration of placebo once daily with or without HU.
Trial: NCT03334617
Drug: AZD9150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD9150 given IV at 200mg every other day of a 1-week lead-in period followed by QW
Trial: NCT03334617
Drug: AZD6738
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD6738 given orally at 240mg twice daily in Cycle 0 Days 1-7, followed by 7 days on treatment in each cycle between Days 22-28
Trial: NCT01044498
Drug: Ortho-Novum® 1/35
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each Ortho-Novum® 1/35 tablet contained 1 mg of norethindrone and 0.035 mg of ethinyl estradiol.
Trial: NCT01415778
Drug: ICI176,334-1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subject will receive single dose of ICI176,334-1
Trial: NCT03633526
Drug: VX-659/TEZ/IVA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VX-659/TEZ/IVA FDC tablet.
Trial: NCT01457053
Drug: Loop diuretics (furosemide, torsemide, bumetanide)
RxNorm normalized name: hydralazine hydrochloride / hydrochlorothiazide / reserpine Oral Tablet [Diuretic Ap-Es]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with ADHF and hypervolemia will be enrolled in a prospective, randomized fashion.~Subjects will be randomized with a computer generated random number function to either ultrafiltration or diuretic therapy within 24 hours of hospitalization for the management of fluid overload.~Patients randomized to diuretic therapy will be treated with intravenous loop diuretics (e.g. furosemide, bumetanide, torsemide). The selection of diuretic, dose and frequency of diuretic administration will be determined by the treating physicians based upon clinical assessment of volume status, response to medication, and perceived safety.
Trial: NCT00113230
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 900 mg/m\^2 by mouth twice a day during days of radiation for all five weeks of therapy.
Trial: NCT00654017
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo comparator to be given per protocol.
Trial: NCT00003165
Drug: doxorubicin-HPMA conjugate
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00667875
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT03799731
Drug: Trifluridine/Tipiracil
RxNorm normalized name: TRIFLURIDINE/TIPIRACIL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lonsurf 35 mg/m² twice daily during 10 days per cycle
Trial: NCT00227292
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 10mg per day for the first week, then 20mg per day till the end of study.
Trial: NCT02429726
Drug: rAdp53
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant adenoviral p53 human gene will be administered by intra chest cavity infusion
Trial: NCT00005798
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide will be given at a dose of 2000 mg/m2 in NS IV over one hour daily on days -6, -5, and -4. (Total dose 6000 mg/m2)
Trial: NCT02224313
Drug: oral estradiol 1.0 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: one tablet of oral estradiol 1.0 mg once a day for 28 days
Trial: NCT03334617
Drug: AZD6738 (ceralasertib) (240 mg or 160 mg)
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD6738 given orally at 240mg or 160mg twice daily in Cycle 0 Days 1-7, followed by 7 days on treatment in each cycle between Days 22-28
Trial: NCT04862533
Drug: Beta-Alanine
RxNorm normalized name: beta-alanine
DrugBank: beta-Alanine (DB03107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive 1150mg of beta-alanine three times a day
Trial: NCT04862533
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive matching placebo three times a day
Trial: NCT02654912
Drug: Reactive Focal Drug Administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This is the experimental arm and is described by a reactive response to passively detected index case of malaria. The reactive response consists of treating all individuals within a defined radius of each RDT-confirmed incident malaria case with dihydroartemisinin-piperaquine (DHAP).
Trial: NCT02958709
Drug: High-dose: RIF, INH, PZA, EMB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: high-dose rifampicin plus standard dose H,Z,E, given for 8 weeks in treatment Arms 1 and 2
Trial: NCT02958709
Drug: High dose: RIF, INH, PZA, LEVO
FDA approved: no
EMA approved: no
PMDA approved: no
Description: high-dose rifampicin plus standard dose H,Z, with levofloxacin substituted for ethambutol for 8 weeks in treatment Arm 2
Trial: NCT02958709
Drug: Standard of care: RIF, INH, PZA, EMB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: standard doses of R,H,Z,E given for 8 weeks in treatment Arm 3, control arm.
Trial: NCT00138060
Drug: 5 fluorouracil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg/m² in bolus in day 1 and 2400 mg/m² in 46 hours perfusion
Trial: NCT02285738
Drug: Simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Daily dose of Simvastatin for 4 weeks
Trial: NCT02231008
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01496742
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching RO5490258 (MetMAb) placebo iv, Day 1 of each 21-day cycle
Trial: NCT01496742
Drug: RO5490258
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg/kg iv, Day 1 of each 21-day cycle
Trial: NCT01062256
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One placebo tablet administered orally as a single dose
Trial: NCT04206020
Drug: SkQ1 Vehicle Solution
RxNorm normalized name: Neisseria meningitidis group B strain NZ98/254 outer membrane vesicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SkQ1 Ophthalmic Solution Vehicle
Trial: NCT04206020
Drug: SkQ1 Ophthalmic Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SkQ1 Ophthalmic Solution
Trial: NCT02137265
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One pill every other day
Trial: NCT00137397
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02620280
Drug: MPDL3280A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MPDL3280A, 1200 mg. will be given i.v. infusion on day 1 q 3 weeks for a total of 8 cycles
Trial: NCT02620280
Drug: Anthra
RxNorm normalized name: Anthralin
DrugBank: Anthralin (DB11157)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AC or EC (adriamycin or epirubicin and cyclophosphamide) or FEC (fluorouracil, epirubicin, and cyclophosphamide) on day 1 every three weeks for 4 cycles to be delivered after surgery
Trial: NCT04124484
Drug: DBPR108 tablet(50mg), Placebo matching DBPR108 tablet(100mg)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One DBPR108 tablet(50mg) administered orally once a day + Two Placebos matching DBPR108 tablet(100mg) administered orally once a day for 12 weeks
Trial: NCT04124484
Drug: DBPR108 tablet(100mg), Placebo matching DBPR108 tablet(50mg), Placebo matching DBPR108 tablet(100mg)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One DBPR108 tablet(100mg) administered orally once a day + One Placebo matching DBPR108 tablet(100mg) administered orally once a day + One Placebo matching DBPR108 tablet(50mg) administered orally once a day for 12 weeks
Trial: NCT04124484
Drug: DBPR108 tablet(100mg), Placebo matching DBPR108 tablet(50mg)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two DBPR108 tablets(100mg) administered orally once a day + One Placebo matching DBPR108 tablet(50mg) administered orally once a day for 12 weeks
Trial: NCT04124484
Drug: Placebo matching DBPR108 tablet(100mg), Placebo matching DBPR108 tablet(50mg)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two Placebos matching DBPR108 tablet(100mg) administered orally once a day + One Placebo matching DBPR108 tablet(50mg) administered orally once a day for 12 weeks
Trial: NCT02221765
Drug: PP1420
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of PP 1420, administered subcutaneously. Dose levels: 8, 16, 32, 64 mg.
Trial: NCT02221765
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% (w/v) saline single-dose, administered subcutaneously
Trial: NCT03258242
Drug: Keluo Xin capsule
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: four capsules at a time, three times a day, taken orally and consecutively for 24 weeks or 48 weeks.
Trial: NCT03258242
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: four placebo capsules at a time, three times a day, taken orally and consecutively for 24 weeks or 48 weeks.
Trial: NCT02355899
Drug: PD P 506 A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PD P 506 A is a dermal patch of 4 cm² in size loaded with 2 mg 5-ALA (as 5-ALA HCl) per cm².
Trial: NCT00890149
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo bid
Trial: NCT01127659
Drug: testosterone
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: intramuscular every 2 weeks
Trial: NCT01127659
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: saline intramuscular every 2 weeks
Trial: NCT03448393
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide will be diluted in an appropriate solution and infused over one hour. The dose will be based on the patient s body weight, at 900 mg/m2/dose after fludarabine infusion on Day -2.
Trial: NCT03957902
Drug: acetylsalicylic acid
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Different dosage effect over platelet COX enzymes, non- neoplastic and neoplastic colonic tissues used as biomarkers of clinical efficacy in CRC chemoprevention
Trial: NCT02178722
Drug: MK-3475
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV infusion
Trial: NCT02178722
Drug: INCB024360
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral daily dosing
Trial: NCT00442390
Drug: hydrocortisone substitution therapy versus withdrawal
RxNorm normalized name: Low-Substituted Hydroxypropyl Cellulose
FDA approved: no
EMA approved: no
PMDA approved: no